These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 19855081)

  • 41. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.
    Polo JM; Dell'Oso T; Ranuncolo SM; Cerchietti L; Beck D; Da Silva GF; Prive GG; Licht JD; Melnick A
    Nat Med; 2004 Dec; 10(12):1329-35. PubMed ID: 15531890
    [TBL] [Abstract][Full Text] [Related]  

  • 42. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas.
    Duan S; Cermak L; Pagan JK; Rossi M; Martinengo C; di Celle PF; Chapuy B; Shipp M; Chiarle R; Pagano M
    Nature; 2012 Jan; 481(7379):90-3. PubMed ID: 22113614
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.
    Goldstein RL; Yang SN; Taldone T; Chang B; Gerecitano J; Elenitoba-Johnson K; Shaknovich R; Tam W; Leonard JP; Chiosis G; Cerchietti L; Melnick A
    J Clin Invest; 2015 Nov; 125(12):4559-71. PubMed ID: 26529251
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
    Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
    Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of signaling through the B cell antigen receptor by the protooncogene product, c-Cbl, requires Syk tyrosine 317 and the c-Cbl phosphotyrosine-binding domain.
    Yankee TM; Keshvara LM; Sawasdikosol S; Harrison ML; Geahlen RL
    J Immunol; 1999 Dec; 163(11):5827-35. PubMed ID: 10570266
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma.
    Ma J; Xing W; Coffey G; Dresser K; Lu K; Guo A; Raca G; Pandey A; Conley P; Yu H; Wang YL
    Oncotarget; 2015 Dec; 6(41):43881-96. PubMed ID: 26575169
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells.
    Motiwala T; Majumder S; Ghoshal K; Kutay H; Datta J; Roy S; Lucas DM; Jacob ST
    J Biol Chem; 2009 Jan; 284(1):455-464. PubMed ID: 18997174
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas.
    Lu X; Nechushtan H; Ding F; Rosado MF; Singal R; Alizadeh AA; Lossos IS
    Blood; 2005 Apr; 105(7):2924-32. PubMed ID: 15591113
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Syk activation by the Src-family tyrosine kinase in the B cell receptor signaling.
    Kurosaki T; Takata M; Yamanashi Y; Inazu T; Taniguchi T; Yamamoto T; Yamamura H
    J Exp Med; 1994 May; 179(5):1725-9. PubMed ID: 7513017
    [TBL] [Abstract][Full Text] [Related]  

  • 50. BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma.
    Saito M; Novak U; Piovan E; Basso K; Sumazin P; Schneider C; Crespo M; Shen Q; Bhagat G; Califano A; Chadburn A; Pasqualucci L; Dalla-Favera R
    Proc Natl Acad Sci U S A; 2009 Jul; 106(27):11294-9. PubMed ID: 19549844
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma.
    Saito M; Gao J; Basso K; Kitagawa Y; Smith PM; Bhagat G; Pernis A; Pasqualucci L; Dalla-Favera R
    Cancer Cell; 2007 Sep; 12(3):280-92. PubMed ID: 17785208
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rituximab inhibits B-cell receptor signaling.
    Kheirallah S; Caron P; Gross E; Quillet-Mary A; Bertrand-Michel J; Fournié JJ; Laurent G; Bezombes C
    Blood; 2010 Feb; 115(5):985-94. PubMed ID: 19965664
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia.
    Chen Z; Shojaee S; Buchner M; Geng H; Lee JW; Klemm L; Titz B; Graeber TG; Park E; Tan YX; Satterthwaite A; Paietta E; Hunger SP; Willman CL; Melnick A; Loh ML; Jung JU; Coligan JE; Bolland S; Mak TW; Limnander A; Jumaa H; Reth M; Weiss A; Lowell CA; Müschen M
    Nature; 2015 May; 521(7552):357-61. PubMed ID: 25799995
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Processing of CD74 by the Intramembrane Protease SPPL2a Is Critical for B Cell Receptor Signaling in Transitional B Cells.
    Hüttl S; Kläsener K; Schweizer M; Schneppenheim J; Oberg HH; Kabelitz D; Reth M; Saftig P; Schröder B
    J Immunol; 2015 Aug; 195(4):1548-63. PubMed ID: 26157172
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma.
    Pasqualucci L; Migliazza A; Basso K; Houldsworth J; Chaganti RS; Dalla-Favera R
    Blood; 2003 Apr; 101(8):2914-23. PubMed ID: 12515714
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation.
    Romero-Camarero I; Jiang X; Natkunam Y; Lu X; Vicente-Dueñas C; Gonzalez-Herrero I; Flores T; Garcia JL; McNamara G; Kunder C; Zhao S; Segura V; Fontan L; Martínez-Climent JA; García-Criado FJ; Theis JD; Dogan A; Campos-Sánchez E; Green MR; Alizadeh AA; Cobaleda C; Sánchez-García I; Lossos IS
    Nat Commun; 2013; 4():1338. PubMed ID: 23299888
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Syk and Bruton's tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt.
    Craxton A; Jiang A; Kurosaki T; Clark EA
    J Biol Chem; 1999 Oct; 274(43):30644-50. PubMed ID: 10521450
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma.
    Ying CY; Dominguez-Sola D; Fabi M; Lorenz IC; Hussein S; Bansal M; Califano A; Pasqualucci L; Basso K; Dalla-Favera R
    Nat Immunol; 2013 Oct; 14(10):1084-92. PubMed ID: 23974956
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells.
    Basso K; Saito M; Sumazin P; Margolin AA; Wang K; Lim WK; Kitagawa Y; Schneider C; Alvarez MJ; Califano A; Dalla-Favera R
    Blood; 2010 Feb; 115(5):975-84. PubMed ID: 19965633
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunohistochemical profile and fluorescence in situ hybridization analysis of diffuse large B-cell lymphoma in northern China.
    Li T; Medeiros LJ; Lin P; Yin H; Littlejohn M; Im W; Lennon PA; Hu P; Jorgensen JL; Liang M; Guo H; Yin CC
    Arch Pathol Lab Med; 2010 May; 134(5):759-65. PubMed ID: 20441508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.